Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal infusion rate of remifentanil for maintaining lung compliance in non-muscle relaxant anesthesia
ChiCTR2200059525Phase 4Not yet recruiting
- Sponsor
- China-Japan Union Hospital of Jilin University
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of remifentanil in thyroid nodule and thyroid neoplasm (2 arms), sponsored by China-Japan Union Hospital of Jilin University. Primary endpoints: Pulmonary static compliance, Peak airway pressure and 1 more. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
remifentanil
03
Conditions
thyroid nodulethyroid neoplasm
Beyond the preview
Go deeper on ChiCTR2200059525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059525.